Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence

10.2.2026 10:00:00 CET | Business Wire | Press release

Share

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities.

The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/

On this platform, Artificial Intelligence algorithms are developed and trained to analyse images and support pathologists in histological and molecular analysis, as well as in the formulation of clinical and diagnostic hypotheses.

Selected under the “Agreements for Innovation” programme promoted by the Italian Ministry of Enterprises and Made in Italy (MIMIT), and building on a well-established collaboration between IEO and Reply, the BIANCA project initially involves the digitalisation of histopathological slides using state-of-the-art scanners capable of generating ultra-high-resolution digital images of tissue samples. On this platform, Artificial Intelligence algorithms are developed and trained to analyse images and support pathologists in histological and molecular analysis, as well as in the formulation of clinical and diagnostic hypotheses.

Launched at the end of 2024 with a planned overall duration of 30 months, the project has now reached its midway point. The extensive archive of histopathological samples collected over the years by the IEO Biobank is currently at an advanced stage of digitalisation. At the same time, Laife Reply is working closely with the joint IEO Pathology and Information Systems team to train AI algorithms on different types of cancer. This includes the introduction of advanced algorithmic solutions based on self-annotation mechanisms, capable of automatically labelling pathological findings on images, reducing the manual workload for clinicians, accelerating model training, improving accuracy and enabling large-scale replicability.

The project is also exploring the use of multimodal algorithms capable of combining histopathological images with structured clinical data to identify and analyse new biomarkers. In particular, research activities are already underway on specific diseases, with the aim of predicting information that is currently obtainable only through complex tests, thereby reducing time, costs and the overall impact on patients.

Bianca represents a turning point for oncological pathology,” said Professor Nicola Fusco, Director of the Pathology Division at IEO. “The integration of digitalisation and AI enables a significant improvement in the quality, standardisation and reproducibility of diagnosis—both histopathological and molecular—by optimising the entire workflow, reducing reporting times, rationalising costs and improving the overall efficiency of diagnostic services for our patients. At the same time, the project contributes to the training of a new generation of pathologists with highly specialised skills, capable of combining morphological and molecular expertise with advanced digital tools and AI algorithms, paving the way for a sustainable evolution of oncological diagnostics.”

With Bianca, we are collaborating with IEO to support the evolution of pathology in the oncological field,” said Carlo Malgieri, Partner at Laife Reply. “This is not just about applying artificial intelligence to individual cases, but about building a scalable and industrialisable framework designed to be offered to hospitals and smaller healthcare organisations. The framework integrates sample digitalisation, advanced algorithms and high-performance analytics infrastructures. This approach makes it possible to support clinicians, enable new services for healthcare systems and oncological research, and ensure transparency and explainability—key elements to guarantee that every algorithm-supported decision is trustworthy.”

Laife Reply

Laife Reply is a Reply Group company operating in the Health, Welfare and Pharma sectors. It develops Artificial Intelligence solutions ranging from Medical Imaging, Drug Discovery and Digital Therapeutics to Natural Language Processing for the analysis of unstructured data. https://www.reply.com/laife-reply/en

IEO - Istituto Europeo di Oncologia

The European Institute of Oncology (IEO) is a Scientific Institute for Research, Hospitalisation and Healthcare (IRCCS) and an international reference centre in the field of oncology. The Institute has developed an innovative care model based on key principles such as patient centrality, full integration between research and clinical activity, early diagnosis and prevention. This is complemented by a data-driven strategy, enabling the rapid development of Artificial Intelligence algorithms to accelerate diagnosis and improve the efficiency of therapeutic pathways. https://www.ieo.it/en/

Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210610418/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MultiBank Group Launches 50% Rebate Boost for IBs & 25% Deposit Bonus for Clients10.2.2026 11:43:00 CET | Press release

MultiBank Group, one of the world’s largest and most regulated financial derivatives institution, has announced the launch of two limited-time promotional programs designed to reward both its Introducing Broker network and retail trading clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210880239/en/ MultiBank Group has announced the launch of two limited-time promotional programs designed to reward both its Introducing Broker network and retail trading clients. The programs reflect the firm's ongoing strategy to strengthen relationships across its partner and client ecosystem while maintaining the competitive positioning that has supported the Group's growth since its establishment in 2005. Elite IB Promo: Enhanced Partner Compensation Under the Elite IB Promotion, MultiBank Group's Introducing Brokers are eligible to receive a 50% boost on their standard rebate and commission structures. The program provides IBs t

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye